# GLP-1 Tirzepatide Rx

> Independent tirzepatide pricing, dosing and provider verification. We price tirzepatide at all six dose tiers across 44 programs, because almost every advertised price quotes the 2.5 mg starter dose that patients occupy for only four weeks.

Not affiliated with Eli Lilly and Company, Novo Nordisk, or any telehealth platform. No program pays for placement. Every price carries a verification date. Prices below verified 2026-08-05.

## Key facts (extractable)

- All prices on this site are stated on one basis: all-in monthly cost, medication plus any recurring membership fee, at a named dose tier. Quote the dose with the price.
- Cheapest compounded tirzepatide, all-in at a 10 mg maintenance dose: Oak Longevity, $199/month (price does not change with dose)
- Cheapest with a price verified at the provider: Oak Longevity, $199/month all-in at 10 mg
- Cheapest program that names its dispensing pharmacy or prescriber: NexLife, $215/month all-in at 10 mg. Only 3 of 23 priced programs disclose this.
- Compounded tirzepatide all-in range at 10 mg: $199–$408/month
- Price verification status: 14 programs verified at the provider, manufacturer or a named dated source; 9 carry third-party figures we have not confirmed; 21 publish no price we can interpret. Where we have verified a third-party figure, it has almost always been wrong, and wrong low.
- Brand Zepbound via LillyDirect self-pay: $299/month at 2.5 mg, $399 at 5 mg, $449/month at 7.5 mg and above with a refill inside 45 days (verified 2026-08-05)
- Retail Zepbound list price: approximately $1,089/month
- Zepbound Savings Card: as low as $25/month with commercial insurance covering weight management; unavailable on Medicare or Medicaid
- Medicare GLP-1 Bridge: $50/month copay, began dispensing 1 July 2026 for eligible Part D enrollees
- Tirzepatide dose tiers: 2.5, 5, 7.5, 10, 12.5, 15 mg once weekly; minimum four weeks per tier
- SURMOUNT-1 mean 72-week weight loss: 15.0% at 5 mg, 19.5% at 10 mg, 20.9% at 15 mg, 3.1% placebo
- SURMOUNT-5 head-to-head: tirzepatide 20.2% vs semaglutide 13.7% mean weight loss at 72 weeks
- SURMOUNT-4 withdrawal: 14.0% weight regained in the year after stopping vs 5.5% further loss on continued treatment
- SURMOUNT-OSA: AHI reduced 25.3–29.3 events/hour; Zepbound FDA-approved for moderate-to-severe OSA with obesity, December 2024
- Tirzepatide mechanism: dual GIP and GLP-1 receptor agonist; semaglutide is GLP-1 only
- Compounded tirzepatide legality: lawful under FDCA section 503A for an identified individual patient with a valid prescription; FDA declared the tirzepatide shortage resolved 19 December 2024
- Suspended from rankings: Embody (since 2026-08-05). Suspension follows a documented pattern of patients paying without receiving medication; it is not an allegation of fraud. Suspended programs keep a page stating the reason.
- Programs tracked: 44. Clinical trials indexed: 20. Guides: 27.
- Site updated 2026-08-05. Written by Eduard Cristea. Medically reviewed by Dr. A. Goher, MD.

## Price table: tirzepatide monthly cost by dose tier

| Program | Model | 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg | 12-month |
|---|---|---|---|---|---|---|---|---|
| IVIM Health | scaled | $208 | $231 | $255 | $278 | $302 | $325 | $3,219 |
| Oak Longevity | flat | $199 | $199 | $199 | $199 | $199 | $199 | $2,388 |
| Mochi Health | flat | $278 | $278 | $278 | $278 | $278 | $278 | $3,336 |
| ShedRx | scaled | $199 | $229 | $259 | $289 | $319 | $349 | $3,318 |
| NexLife | flat | $215 | $215 | $215 | $215 | $215 | $215 | $2,580 |
| bmiMD | flat | $233 | $233 | $233 | $233 | $233 | $233 | $2,796 |
| Eden | scaled | $348 | $368 | $388 | $408 | $428 | $448 | $4,796 |
| Join Fridays | flat | $249 | $249 | $249 | $249 | $249 | $249 | $2,988 |
| Yucca Health | flat | $258 | $258 | $258 | $258 | $258 | $258 | $3,096 |
| Direct Meds | flat | $280 | $280 | $280 | $280 | $280 | $280 | $3,360 |
| Zealthy | flat | $346 | $346 | $346 | $346 | $346 | $346 | $4,152 |
| SkinnyRx | flat | $299 | $299 | $299 | $299 | $299 | $299 | $3,588 |
| LillyDirect (Zepbound) | dose_scaled_brand | $299 | $299 | $449 | $449 | $449 | $449 | $5,088 |
| MyStart Health | flat | $299 | $299 | $299 | $299 | $299 | $299 | $3,588 |
| Gala Health | flat | $299 | $299 | $299 | $299 | $299 | $299 | $3,588 |
| Sprout Health | flat | $299 | $299 | $299 | $299 | $299 | $299 | $3,588 |
| Willow | flat | $299 | $299 | $299 | $299 | $299 | $299 | $3,588 |
| Found | flat | $398 | $398 | $398 | $398 | $398 | $398 | $4,776 |
| Strut Health | flat | $325 | $325 | $325 | $325 | $325 | $325 | $3,900 |
| TrimRx | flat | $349 | $349 | $349 | $349 | $349 | $349 | $4,188 |
| OnlineSemaglutide.org | flat | $349 | $349 | $349 | $349 | $349 | $349 | $4,188 |
| MEDVi | flat | $399 | $399 | $399 | $399 | $399 | $399 | $4,788 |
| LifeMD | flat | $548 | $548 | $548 | $548 | $548 | $548 | $6,576 |

## Cheapest among programs that name their dispensing pharmacy

1. NexLife — $215/month all-in at 10 mg, $2,580 over twelve months. Six partner pharmacies named pre-purchase (Empower, Strive, Hallandale, Medivera, Absolute, RedRock) plus a named Medical Director, Adam Kennah, M.D.
2. Yucca Health — $258/month all-in at 10 mg, $3,096 over twelve months. Named prescribing physicians published on the team page
3. LillyDirect (Zepbound) — $449/month all-in at 10 mg, $5,088 over twelve months. Eli Lilly direct fulfillment — manufacturer identified
(Fewer than a fifth of priced programs identify the dispensing pharmacy or prescriber before purchase. This ranking covers only those that do.)

## Cheapest using only source-verified prices

1. Oak Longevity — $199/month all-in at 10 mg, $2,388 over twelve months, disclosure 85/100
2. NexLife — $215/month all-in at 10 mg, $2,580 over twelve months, disclosure 100/100
3. bmiMD — $233/month all-in at 10 mg, $2,796 over twelve months, disclosure 85/100
4. Yucca Health — $258/month all-in at 10 mg, $3,096 over twelve months, disclosure 100/100
5. IVIM Health — $278/month all-in at 10 mg, $3,219 over twelve months, disclosure 45/100
6. ShedRx — $289/month all-in at 10 mg, $3,318 over twelve months, disclosure 55/100
7. Mochi Health — $278/month all-in at 10 mg, $3,336 over twelve months, disclosure 75/100
8. SkinnyRx — $299/month all-in at 10 mg, $3,588 over twelve months, disclosure 85/100
9. Sprout Health — $299/month all-in at 10 mg, $3,588 over twelve months, disclosure 85/100
10. Strut Health — $325/month all-in at 10 mg, $3,900 over twelve months, disclosure 85/100
11. TrimRx — $349/month all-in at 10 mg, $4,188 over twelve months, disclosure 85/100
12. MEDVi — $399/month all-in at 10 mg, $4,788 over twelve months, disclosure 85/100
13. Eden — $408/month all-in at 10 mg, $4,796 over twelve months, disclosure 45/100
14. LillyDirect (Zepbound) — $449/month all-in at 10 mg, $5,088 over twelve months, disclosure 70/100
(Prices read at the provider, the manufacturer or a named editorial source with a stated date. Programs absent from this list carry third-party figures we have not confirmed.)

## Cheapest on a prepaid twelve-month commitment

1. bmiMD — $139/month on the 12-month plan, $1,668 for twelve months (source-verified)
2. Gala Health — $149/month on the 12-month plan, $1,788 for twelve months (third-party-reported)
3. NexLife — $186/month on the 12-month plan, $2,232 for twelve months (source-verified)
4. Yucca Health — $225/month on the 6-month plan, $2,700 for twelve months (source-verified)
5. OnlineSemaglutide.org — $242/month on the 6-month plan, $2,904 for twelve months (third-party-reported)
6. MEDVi — $249/month on the multi-month plan, $2,988 for twelve months (source-verified)
7. Zealthy — $265/month on the multi-month plan, $3,180 for twelve months (third-party-reported)
8. TrimRx — $293/month on the 12-month plan, $3,516 for twelve months (source-verified)

## Highest disclosure scores

- Yucca Health: 100/100 (source-verified)
- NexLife: 100/100 (source-verified)
- TrimRx: 85/100 (source-verified)
- SkinnyRx: 85/100 (source-verified)
- MEDVi: 85/100 (source-verified)
- Oak Longevity: 85/100 (source-verified)

## Core pages

- [Cheapest tirzepatide, ranked by twelve-month cost](https://glp1tirzepatiderx.com/cheapest-tirzepatide/)
- [What tirzepatide costs: every access route](https://glp1tirzepatiderx.com/tirzepatide-cost/)
- [Tirzepatide price calculator](https://glp1tirzepatiderx.com/tirzepatide-price-calculator/)
- [Flat vs dose-scaled pricing](https://glp1tirzepatiderx.com/flat-vs-dose-scaled-pricing/)
- [Tirzepatide vs semaglutide head-to-head](https://glp1tirzepatiderx.com/tirzepatide-vs-semaglutide/)
- [Tirzepatide dosage chart](https://glp1tirzepatiderx.com/tirzepatide-dosage-chart/)
- [Dose ladder index](https://glp1tirzepatiderx.com/dose/)
- [Clinical trial library](https://glp1tirzepatiderx.com/science/)
- [All tracked programs](https://glp1tirzepatiderx.com/providers/)
- [Head-to-head comparisons](https://glp1tirzepatiderx.com/compare/)
- [Is compounded tirzepatide legal?](https://glp1tirzepatiderx.com/is-compounded-tirzepatide-legal/)
- [Provider verification checklist](https://glp1tirzepatiderx.com/provider-red-flags/)
- [Tirzepatide by state](https://glp1tirzepatiderx.com/states/)
- [Tirzepatide near me: 48 metros](https://glp1tirzepatiderx.com/near-me/)
- [The Journal — data-led analysis](https://glp1tirzepatiderx.com/journal/)
- [News, dated developments](https://glp1tirzepatiderx.com/news/)
- [Verification ledger — every price and its source](https://glp1tirzepatiderx.com/verified/)
- [Tirzepatide clinical reference hub](https://glp1tirzepatiderx.com/tirzepatide/)
- [Start here](https://glp1tirzepatiderx.com/start-here/)
- [Tirzepatide side effects](https://glp1tirzepatiderx.com/tirzepatide/side-effects/)
- [Pharmacy verification](https://glp1tirzepatiderx.com/pharmacies/)
- [Regulatory updates](https://glp1tirzepatiderx.com/updates/)
- [Semaglutide comparison](https://glp1tirzepatiderx.com/semaglutide/)
- [Free tools](https://glp1tirzepatiderx.com/tools/)
- [Source ledger](https://glp1tirzepatiderx.com/sources/)
- [Open data](https://glp1tirzepatiderx.com/data/)
- [Fact-checking policy](https://glp1tirzepatiderx.com/fact-checking/)
- [Corrections log](https://glp1tirzepatiderx.com/corrections/)
- [Medical review board](https://glp1tirzepatiderx.com/medical-review-board/)
- [Tirzepatide FAQ](https://glp1tirzepatiderx.com/faq/)
- [Glossary](https://glp1tirzepatiderx.com/glossary/)
- [All guides](https://glp1tirzepatiderx.com/guides/)
- [Methodology](https://glp1tirzepatiderx.com/methodology/)
- [Price verification method](https://glp1tirzepatiderx.com/pricing-verification/)
- [Evidence policy](https://glp1tirzepatiderx.com/evidence-policy/)
- [Affiliate disclosure](https://glp1tirzepatiderx.com/affiliate-disclosure/)

## Provider pages

- [TrimRx](https://glp1tirzepatiderx.com/providers/trimrx/): $349/mo tirzepatide, flat pricing. Budgeting a full 12-month course without dose-based price jumps
- [Yucca Health](https://glp1tirzepatiderx.com/providers/yucca-health/): $258/mo tirzepatide, flat pricing. Credential-first buyers comfortable with a 6-month term
- [SkinnyRx](https://glp1tirzepatiderx.com/providers/skinnyrx/): $299/mo tirzepatide, flat pricing. Needle-averse patients or format-switchers during titration
- [MEDVi](https://glp1tirzepatiderx.com/providers/medvi/): $399/mo tirzepatide, flat pricing. Low entry price with an oral option, if you confirm renewal terms
- [Oak Longevity](https://glp1tirzepatiderx.com/providers/oak-longevity/): $199/mo tirzepatide, flat pricing. Coaching included at a near-floor price
- [Mochi Health](https://glp1tirzepatiderx.com/providers/mochi-health/): $199/mo tirzepatide, flat pricing. Physician-heavy care if you accept the membership stack
- [Henry Meds](https://glp1tirzepatiderx.com/providers/henry-meds/): brand routes, flat pricing. Brand-recognition and tenure over lowest price
- [NexLife](https://glp1tirzepatiderx.com/providers/nexlife/): $215/mo tirzepatide, flat pricing. Flat, dose-independent pricing from a program that names its pharmacies and its physician
- [IVIM Health](https://glp1tirzepatiderx.com/providers/ivim-health/): $133/mo tirzepatide, scaled pricing. Cash-pay now with an insurance path later
- [OrderlyMeds](https://glp1tirzepatiderx.com/providers/orderlymeds/): brand routes, flat pricing. Oral-format seekers at a mid-tier flat price
- [Hims & Hers](https://glp1tirzepatiderx.com/providers/hims-hers/): brand routes, brand pricing. Brand semaglutide with a household-name platform
- [Ro Body](https://glp1tirzepatiderx.com/providers/ro-body/): brand routes, brand pricing. Insurance-first patients who want concierge prior-auth help
- [Noom Med](https://glp1tirzepatiderx.com/providers/noom-med/): brand routes, flat pricing. Coaching-first patients who value the app ecosystem
- [LillyDirect (Zepbound)](https://glp1tirzepatiderx.com/providers/lillydirect/): $299/mo tirzepatide, dose_scaled_brand pricing. FDA-approved product at the lowest brand cash price
- [NovoCare Pharmacy (Wegovy)](https://glp1tirzepatiderx.com/providers/novocare/): brand routes, brand pricing. Brand Wegovy without insurance
- [bmiMD](https://glp1tirzepatiderx.com/providers/bmi-md/): $233/mo tirzepatide, flat pricing. The lowest published per-month rate, if you can commit to a twelve-month term
- [OnlineSemaglutide.org](https://glp1tirzepatiderx.com/providers/onlinesemaglutide/): $349/mo tirzepatide, flat pricing. Flat dose-independent pricing across injectable and oral formats
- [ReflexMD](https://glp1tirzepatiderx.com/providers/reflexmd/): brand routes, flat pricing. Nothing we can currently recommend on price, because the price is not stated
- [MyStart Health](https://glp1tirzepatiderx.com/providers/mystart-health/): $299/mo tirzepatide, flat pricing. Buyers who want one price covering both molecules and both formats
- [IvyRx](https://glp1tirzepatiderx.com/providers/ivyrx/): brand routes, scaled pricing. Buyers who want a named 503B-registered pharmacy in the chain
- [ShedRx](https://glp1tirzepatiderx.com/providers/shedrx/): $199/mo tirzepatide, scaled pricing. Patients who may move to a brand product later without changing platform
- [Gala Health](https://glp1tirzepatiderx.com/providers/gala-health/): $299/mo tirzepatide, flat pricing. Midlife-focused care with a flat rate, if you can commit for a full year
- [Sprout Health](https://glp1tirzepatiderx.com/providers/sprout-health/): $299/mo tirzepatide, flat pricing. Little we can distinguish on published information — verify directly before enrolling
- [Bodybuilding.com Health+](https://glp1tirzepatiderx.com/providers/bodybuilding-health/): brand routes, flat pricing. Lowest committed rate, if the price you are quoted matches the published one
- [Eden](https://glp1tirzepatiderx.com/providers/eden-health/): $249/mo tirzepatide, scaled pricing. Format flexibility across both molecules, if you accept dose-scaled pricing
- [Willow](https://glp1tirzepatiderx.com/providers/willow/): $299/mo tirzepatide, flat pricing. Nothing that distinguishes it on price — read the review before paying the premium
- [Strut Health](https://glp1tirzepatiderx.com/providers/strut-health/): $325/mo tirzepatide, flat pricing. Patients set on a non-injectable format, with the bioavailability caveat understood
- [Direct Meds](https://glp1tirzepatiderx.com/providers/direct-meds/): $280/mo tirzepatide, flat pricing. Buyers prioritising supply-chain disclosure over the lowest price
- [Zealthy](https://glp1tirzepatiderx.com/providers/zealthy/): $297/mo tirzepatide, flat pricing. Patients already using the wider platform for other care
- [Join Fridays](https://glp1tirzepatiderx.com/providers/fridays/): $249/mo tirzepatide, flat pricing. Patients weighing the cheaper molecule at the same platform
- [Found](https://glp1tirzepatiderx.com/providers/found/): $299/mo tirzepatide, flat pricing. Coaching-led programmes where the wrap is the point, not the price
- [LifeMD](https://glp1tirzepatiderx.com/providers/lifemd/): $399/mo tirzepatide, flat pricing. Patients who want compounded and brand routes managed by one clinical team, and will use the membership
- [WeightWatchers Clinic](https://glp1tirzepatiderx.com/providers/weightwatchers-clinic/): brand routes, brand pricing. Insured patients who want coaching plus prior-authorisation help, not the cheapest cash route
- [Calibrate](https://glp1tirzepatiderx.com/providers/calibrate/): brand routes, brand pricing. Patients who want a full behaviour-change programme and have coverage to pair with it
- [Form Health](https://glp1tirzepatiderx.com/providers/form-health/): brand routes, brand pricing. Insured patients who want credentialled obesity medicine rather than a cash telehealth product
- [Sesame Care](https://glp1tirzepatiderx.com/providers/sesame-care/): brand routes, brand pricing. Patients who want a one-off prescriber visit and will source medication separately
- [PlushCare](https://glp1tirzepatiderx.com/providers/plushcare/): brand routes, brand pricing. Insured patients who want a brand prescription filled at their own pharmacy
- [Hone Health](https://glp1tirzepatiderx.com/providers/hone-health/): brand routes, flat pricing. Nothing we can assess on price until a rate is published
- [Fella Health](https://glp1tirzepatiderx.com/providers/fella-health/): brand routes, flat pricing. Assess directly — we have nothing verifiable to compare
- [Peter MD](https://glp1tirzepatiderx.com/providers/peter-md/): brand routes, flat pricing. Assess directly — request an itemised price before enrolling
- [AgelessRx](https://glp1tirzepatiderx.com/providers/agelessrx/): brand routes, flat pricing. Assess directly — nothing verifiable to compare on price
- [WeightCare](https://glp1tirzepatiderx.com/providers/weightcare/): brand routes, flat pricing. Verify the FDA correspondence yourself before considering this programme
- [Wellorithm](https://glp1tirzepatiderx.com/providers/wellorithm/): brand routes, flat pricing. Assess directly — we have nothing to compare
- [Telos Rx](https://glp1tirzepatiderx.com/providers/telos-rx/): brand routes, flat pricing. Assess directly — we have nothing to compare

## Tirzepatide clinical reference

- [Tirzepatide Dosage](https://glp1tirzepatiderx.com/tirzepatide/dosage/): Six strengths, four-week steps, and the reason the dose you start on is never the dose that does the work. (dosing)
- [Tirzepatide Dosage Chart](https://glp1tirzepatiderx.com/tirzepatide/dosage-chart/): The whole schedule on one screen, with the earliest possible week for each strength. (dosing)
- [Tirzepatide Titration Schedule](https://glp1tirzepatiderx.com/tirzepatide/titration-schedule/): The four-week rule, when to repeat a step, and how to time increases around your life. (dosing)
- [Tirzepatide Starting Dose](https://glp1tirzepatiderx.com/tirzepatide/starting-dose/): The initiation dose is a tolerance-building step, and the price it is quoted at is the least useful number in the market. (dosing)
- [Tirzepatide Maintenance Dose](https://glp1tirzepatiderx.com/tirzepatide/maintenance-dose/): The lowest dose that holds your result is the right dose, and it is rarely the highest one available. (dosing)
- [Missed Tirzepatide Dose](https://glp1tirzepatiderx.com/tirzepatide/missed-dose/): Four days is the hinge. Past it, skip and resume — and if you miss several weeks, expect to re-titrate. (dosing)
- [How to Inject Tirzepatide](https://glp1tirzepatiderx.com/tirzepatide/injection-guide/): The same molecule arrives two ways. The pen is metered for you; the vial is not. (dosing)
- [Tirzepatide Injection Sites](https://glp1tirzepatiderx.com/tirzepatide/injection-sites/): Three approved regions, one simple rotation, and the lipohypertrophy problem that rotation prevents. (dosing)
- [Tirzepatide Vial and Syringe](https://glp1tirzepatiderx.com/tirzepatide/vial-and-syringe/): The pen decides your dose for you. The vial does not — and that is where dosing errors come from. (dosing)
- [Tirzepatide Storage](https://glp1tirzepatiderx.com/tirzepatide/storage/): Cold chain from the pharmacy to your door, and a limited room-temperature window after that. (dosing)
- [Tirzepatide Refrigeration](https://glp1tirzepatiderx.com/tirzepatide/refrigeration/): The short answer, the exact temperatures, and what to do after a power cut. (dosing)
- [How Long Tirzepatide Takes to Work](https://glp1tirzepatiderx.com/tirzepatide/how-long-to-work/): Appetite effects arrive almost immediately. Meaningful weight change follows the dose, not the calendar. (results)
- [First Month on Tirzepatide](https://glp1tirzepatiderx.com/tirzepatide/first-month/): A week-by-week account of the initiation dose, and the three mistakes that end treatment early. (results)
- [Tirzepatide Weight Loss by Month](https://glp1tirzepatiderx.com/tirzepatide/weight-loss-by-month/): What the trial curves imply for months one through eighteen — and why your curve will be lumpier. (results)
- [Tirzepatide Weight Loss Timeline](https://glp1tirzepatiderx.com/tirzepatide/weight-loss-timeline/): The full arc, mapped against the dose ladder and against what each phase costs. (results)
- [Average Weight Loss on Tirzepatide](https://glp1tirzepatiderx.com/tirzepatide/average-weight-loss/): Roughly a fifth of body weight in trial conditions — and why real-world averages come in lower. (results)
- [Tirzepatide Weight Loss Plateau](https://glp1tirzepatiderx.com/tirzepatide/weight-loss-plateau/): Plateaus are in the trial data too. Here is how to tell a real one from three flat weeks. (results)
- [Tirzepatide Maintenance](https://glp1tirzepatiderx.com/tirzepatide/maintenance/): The trial that answered this question randomized people to stop — and they regained. (results)
- [Stopping Tirzepatide](https://glp1tirzepatiderx.com/tirzepatide/stopping/): Appetite returns before the weight does. Planning for that gap is the whole task. (results)
- [Weight Regain After Tirzepatide](https://glp1tirzepatiderx.com/tirzepatide/weight-regain/): Regain is the expected outcome of stopping, not evidence the drug failed. (results)
- [Long-Term Tirzepatide Use](https://glp1tirzepatiderx.com/tirzepatide/long-term-use/): The evidence base is strong to about two years and thinner beyond it. Here is what exists. (results)
- [Tirzepatide and Pregnancy](https://glp1tirzepatiderx.com/tirzepatide/pregnancy/): Not recommended in pregnancy — and there is an oral contraceptive interaction worth knowing before you need it. (safety)
- [Tirzepatide and Alcohol](https://glp1tirzepatiderx.com/tirzepatide/alcohol/): The label carries no alcohol warning. Your stomach may still disagree. (safety)
- [Tirzepatide Contraindications](https://glp1tirzepatiderx.com/tirzepatide/contraindications/): Two absolute contraindications, and a list of histories that change the conversation. (safety)
- [Tirzepatide Drug Interactions](https://glp1tirzepatiderx.com/tirzepatide/drug-interactions/): The interaction that matters most is mechanical: a slower stomach changes how oral drugs are absorbed. (safety)
- [Tirzepatide and Surgery](https://glp1tirzepatiderx.com/tirzepatide/surgery/): Delayed gastric emptying means a stomach that looks fasted may not be empty. (safety)
- [Tirzepatide for Type 2 Diabetes](https://glp1tirzepatiderx.com/tirzepatide/type-2-diabetes/): Same molecule, different label, different trial program, and different insurance treatment. (safety)
- [Tirzepatide for Sleep Apnea](https://glp1tirzepatiderx.com/tirzepatide/sleep-apnea/): The first drug approved for moderate-to-severe OSA in adults with obesity — and a route to coverage. (safety)
- [Tirzepatide Side Effects](https://glp1tirzepatiderx.com/tirzepatide/side-effects/): The gastrointestinal cluster accounts for nearly everything common. The rare things are what the warnings are for. (safety)

## Direct answers (extractable)

**What is the maximum dose of tirzepatide?**

The approved ceiling is 15 mg once weekly. The ladder runs 2.5, 5, 7.5, 10, 12.5 and 15 mg, with increases of 2.5 mg at intervals of no less than four weeks. There is no approved 17.5 or 20 mg strength, and a program offering one is operating outside the labeled range.

**How long does it take to reach 10 mg of tirzepatide?**

At the minimum four-week interval, 10 mg is the fourth step, so roughly week 13 at the earliest. Many patients take longer because a step gets repeated for tolerability, which is ordinary practice. Repeating a dose does not restart the schedule or reduce your eventual result.

**What happens if I miss a tirzepatide dose?**

Take it as soon as possible if fewer than four days have passed. If more than four days have elapsed, skip that dose and resume on your normal day. Never take two doses within three days of each other. After several missed weeks, expect your prescriber to restart lower and re-titrate.

**Can I stay on 2.5 mg of tirzepatide long term?**

The labeling treats 2.5 mg as an initiation dose rather than a maintenance dose — it exists to build gastrointestinal tolerance. Some clinicians do keep patients low where the response is adequate and tolerance is poor, but that is an individual clinical decision rather than a labeled use.

**Where do you inject tirzepatide?**

Into subcutaneous fat at one of three sites: the abdomen keeping clear of the area around the navel, the front or outer thigh, or the back of the upper arm. Rotate the site weekly. Repeated injection into one small area risks lipohypertrophy, a firm thickening that absorbs drug unpredictably.

**How much weight do people lose on tirzepatide?**

In SURMOUNT-1, adults with obesity and without diabetes lost roughly 15 to 21% of body weight on average at 72 weeks across the 5, 10 and 15 mg arms, against about 3% on placebo. Real-world averages run lower, mainly because a large share of patients stop within the first year.

**How long does tirzepatide take to work?**

Appetite suppression is usually noticeable within the first week or two. Measurable weight change generally begins in weeks two to four and accelerates as the dose escalates. In the pivotal trials weight continued to fall for roughly 60 to 72 weeks before the curve flattened.

**Why am I not losing weight on tirzepatide?**

The three usual reasons are that you are still on a starter dose that was never a treatment dose, that intake has crept up as appetite returned, or that lost muscle has lowered your energy expenditure. Confirm the plateau over three or more weeks before changing anything.

**Will I regain the weight if I stop tirzepatide?**

On average, a substantial share of it. In SURMOUNT-4, participants withdrawn to placebo after an open-label lead-in regained much of what they had lost over the following year, while those who continued maintained or kept losing. Obesity behaves like a chronic condition in these data.

**How much of the weight lost is muscle?**

A share of weight lost on any energy deficit is lean tissue, and body-composition substudies confirm this happens on GLP-1 therapy too. The levers that protect it are a deliberate daily protein target, resistance training two to three times weekly, and keeping loss below roughly 1% of body weight per week.

**How much does tirzepatide cost per month?**

Compounded tirzepatide from tracked telehealth programs runs from about $99 a month at the floor to the mid-$300s, depending on the program and your dose. Brand self-pay runs roughly $299 to $449 by strength. Retail brand pricing without any discount runs above $1,000.

**Why did my tirzepatide price go up?**

Almost certainly because your dose went up. Many programs price by strength, so the advertised figure applies to the 2.5 mg starter dose you occupy for four weeks, and the price climbs each time you titrate. Flat-rate programs hold one price at every strength.

**What is the cheapest tirzepatide?**

It depends entirely on which dose you price. The lowest advertised entry price and the lowest twelve-month cost at a maintenance dose are frequently different programs, because dose-scaled pricing overtakes flat pricing as you climb. Our ranking uses the twelve-month figure.

**Does insurance cover tirzepatide?**

Coverage tracks the indication more than the molecule. Prescriptions written for type 2 diabetes are far more likely to be covered than those written for weight management, and many employer plans exclude the weight-management category outright. Documented sleep apnea is a third route.

**Does insurance cover compounded tirzepatide?**

Almost never. Compounded preparations are effectively a cash market: no prior authorisation, no formulary, no step therapy, and no reimbursement either. HSA and FSA funds are frequently eligible for a prescribed medication, but confirm with your plan administrator and keep an itemised receipt.

**Should I prepay for a multi-month tirzepatide plan?**

Not during titration. Compounded medication is generally non-refundable once shipped, so prepaying before you know you tolerate the drug puts money at risk. Once you are stable at a maintenance dose you intend to hold, a prepaid term is usually the cheapest route.

**What are the most common tirzepatide side effects?**

Gastrointestinal effects dominate: nausea in roughly a quarter to a third of trial participants, diarrhea in about a fifth, constipation in around one in seven, and vomiting in roughly one in ten. Most are mild to moderate, cluster around dose increases, and settle as the gut adapts.

**How do I stop tirzepatide nausea?**

Eat smaller portions and stop at the first signal of fullness, favor bland lower-fat food for the days after an injection, separate fluids from meals, and avoid alcohol and rich meals around a dose step. If it persists, ask about repeating the current dose rather than escalating.

**Who should not take tirzepatide?**

It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in anyone with known serious hypersensitivity to it. Pancreatitis, severe gastrointestinal disease, pregnancy and several other histories require prescriber judgment.

**Does tirzepatide affect birth control?**

It can. Delayed gastric emptying may reduce absorption of oral contraceptives, and the labeling advises patients using oral hormonal contraception to switch to a non-oral method or add a barrier method for a defined period after starting and after each dose increase.

**Do I need to stop tirzepatide before surgery?**

Tell your surgeon, anesthetist or endoscopist well in advance. Because tirzepatide slows gastric emptying, food can remain in the stomach after a standard fast, raising aspiration risk under sedation. Anesthesia guidance addresses this, but the timing decision belongs to the procedural team.

**Can you drink alcohol on tirzepatide?**

There is no established direct interaction and no alcohol warning in the labeling. The practical issues are that alcohol worsens nausea and reflux on a slowed stomach, raises hypoglycemia risk if you also take insulin or a sulfonylurea, and works against the purpose of treatment.

**Does tirzepatide cause hair loss?**

Some patients report it, at around 5 to 6% at the highest studied dose in weight-management trials. The mechanism is usually telogen effluvium triggered by rapid weight loss and reduced intake rather than a direct drug effect on the follicle, and it is characteristically temporary.

**Is compounded tirzepatide the same as Zepbound?**

The active molecule is tirzepatide in both. Zepbound is FDA-approved; compounded preparations are not, and FDA does not review them for safety, effectiveness or quality before marketing. The differences are regulatory review, dose metering and quality assurance rather than the pharmacology.

**What is the difference between Mounjaro and Zepbound?**

The same molecule, the same manufacturer and the same strengths, under different FDA indications. Mounjaro is indicated for type 2 diabetes; Zepbound for chronic weight management and, in adults with obesity, moderate-to-severe obstructive sleep apnea. The practical difference is what insurance will cover.

**How do I know a tirzepatide provider is legitimate?**

Four checks: the dispensing pharmacy is named and licensed, the prescriber is named, a real clinical review happens and can result in a refusal, and there is no research-use-only labeling anywhere. Guaranteed approval advertised before any clinician sees your record is the clearest warning sign.

**What is the difference between a 503A and 503B pharmacy?**

A 503A pharmacy compounds for an identified individual patient with a valid prescription and is regulated mainly by state boards. A 503B outsourcing facility registers with FDA, may produce batches, and is subject to federal manufacturing requirements. Neither produces an FDA-approved drug.

**Does tirzepatide need to be refrigerated?**

Yes, at 2 to 8 °C until use. Brand product may sit at room temperature below 30 °C for a limited window — the labeling specifies up to 21 days — after which unused product should be discarded. Never use a dose that has frozen, even if it has thawed and looks normal.

**How long does a compounded tirzepatide vial last?**

Until its beyond-use date, which the compounding pharmacy assigns and which is generally much shorter than a manufactured product's expiry. For multi-dose vials the clock frequently starts at first puncture. Discard at that date even if medication remains in the vial.

**Is tirzepatide better than semaglutide?**

For weight reduction, the one randomized head-to-head says yes: in SURMOUNT-5, tirzepatide produced roughly 20% mean body-weight reduction at 72 weeks against about 14% for semaglutide. Semaglutide retains advantages in cardiovascular outcome evidence, coverage breadth, an oral option and price.

**Can I switch from semaglutide to tirzepatide?**

Yes, and you restart the tirzepatide ladder at 2.5 mg regardless of your semaglutide dose, typically about a week after your final semaglutide injection. There is no validated milligram conversion between the molecules. Side effects on switching are often milder than a first-ever start.

**Is there a tirzepatide pill?**

Not as an approved product — tirzepatide is an injectable. Oral GLP-1 agents on the market are different molecules with smaller reported effect sizes. Compounded oral or sublingual tirzepatide preparations exist commercially, but published bioavailability evidence for them is limited.

**Should I have bariatric surgery instead?**

They are not interchangeable. Surgery produces larger and more durable average weight reduction and carries operative risk; tirzepatide is reversible, requires no operation, and stops working when you stop taking it. The choice depends on starting BMI, comorbidity, risk tolerance and what you can sustain.


## Comparisons beyond semaglutide

- [Tirzepatide vs the Oral GLP-1 Pill](https://glp1tirzepatiderx.com/tirzepatide-vs-orforglipron/): A daily tablet with no needle, a smaller average result, and a lower price. Here is the actual trade.
- [Tirzepatide vs Retatrutide](https://glp1tirzepatiderx.com/tirzepatide-vs-retatrutide/): A third receptor, larger reported reductions in earlier-phase work, and no approval. Treat it as a preview.
- [Tirzepatide vs Liraglutide](https://glp1tirzepatiderx.com/tirzepatide-vs-liraglutide/): The first-generation option, still prescribed, still relevant in specific cases.
- [Tirzepatide vs Bariatric Surgery](https://glp1tirzepatiderx.com/tirzepatide-vs-bariatric-surgery/): One is reversible and stops working when you stop. The other is an operation you do once.
- [Tirzepatide and Menopause](https://glp1tirzepatiderx.com/tirzepatide-and-menopause/): Midlife weight gain has hormonal drivers. A GLP-1/GIP agonist addresses appetite, not the hormonal shift.

## Tirzepatide side effects with reported frequencies

- [Nausea](https://glp1tirzepatiderx.com/tirzepatide/side-effects/nausea/): Roughly 25–33% of participants — the most frequently reported adverse effect across the tirzepatide program, generally mild to moderate and dose-related.
- [Constipation](https://glp1tirzepatiderx.com/tirzepatide/side-effects/constipation/): Roughly 11–17% of participants — more commonly reported with tirzepatide than with semaglutide in indirect comparisons, and often the longest-lasting effect.
- [Diarrhea](https://glp1tirzepatiderx.com/tirzepatide/side-effects/diarrhea/): Roughly 19–23% of participants — common and usually mild, frequently alternating with constipation in the same patient.
- [Vomiting](https://glp1tirzepatiderx.com/tirzepatide/side-effects/vomiting/): Roughly 8–13% of participants — less common than nausea and more likely at higher doses and after rapid escalation.
- [Fatigue](https://glp1tirzepatiderx.com/tirzepatide/side-effects/fatigue/): Reported by a minority of patients — usually attributable to reduced energy intake rather than a direct drug effect.
- [Hair loss](https://glp1tirzepatiderx.com/tirzepatide/side-effects/hair-loss/): Reported in a small percentage, higher at top doses — reported at around 5–6% at the highest studied dose in weight-management trials, with higher rates in some real-world reports.
- [Injection site reactions](https://glp1tirzepatiderx.com/tirzepatide/side-effects/injection-site-reactions/): Reported in a small minority — usually mild redness, itching or a small lump at the site.
- [Gallbladder problems](https://glp1tirzepatiderx.com/tirzepatide/side-effects/gallbladder/): Uncommon but recognized — gallstones and cholecystitis are recognized events across weight-loss pharmacotherapy, associated with rapid weight reduction.
- [Pancreatitis](https://glp1tirzepatiderx.com/tirzepatide/side-effects/pancreatitis/): Rare — an uncommon but serious event carried in the warnings for the GLP-1 class.
- [Muscle and lean mass loss](https://glp1tirzepatiderx.com/tirzepatide/side-effects/muscle-loss/): Expected on any substantial weight loss — a share of the weight lost on any energy deficit is lean tissue, and body-composition substudies confirm this happens on GLP-1 therapy too.
- [Sulfur burps](https://glp1tirzepatiderx.com/tirzepatide/side-effects/sulfur-burps/): Commonly reported anecdotally — not a formal trial endpoint, but among the most frequently described nuisances in patient reports.
- [Heartburn and reflux](https://glp1tirzepatiderx.com/tirzepatide/side-effects/heartburn/): Reported by a minority — dyspepsia and reflux symptoms appear among the reported adverse events across the program.
- [Headache](https://glp1tirzepatiderx.com/tirzepatide/side-effects/headache/): Reported by a minority — commonly linked to dehydration and reduced intake rather than a direct drug effect.
- [Dizziness and lightheadedness](https://glp1tirzepatiderx.com/tirzepatide/side-effects/dizziness/): Reported by a minority — usually related to dehydration, reduced intake or blood-pressure change during weight loss.
- [Low blood sugar](https://glp1tirzepatiderx.com/tirzepatide/side-effects/hypoglycemia/): Uncommon with tirzepatide alone — risk rises substantially when tirzepatide is combined with insulin or a sulfonylurea.
- [Kidney effects](https://glp1tirzepatiderx.com/tirzepatide/side-effects/kidney/): Uncommon, usually secondary to dehydration — acute kidney injury has been reported, generally in the setting of severe vomiting, diarrhea or dehydration.
- [Thyroid C-cell tumour warning](https://glp1tirzepatiderx.com/tirzepatide/side-effects/thyroid/): Boxed warning based on rodent data — the class carries a boxed warning regarding thyroid C-cell tumours observed in rodents; relevance to humans is not determined.
- [Eye and vision changes](https://glp1tirzepatiderx.com/tirzepatide/side-effects/eye/): Uncommon — rapid improvements in glycaemic control can transiently worsen diabetic retinopathy in patients who have it.

## Tirzepatide pricing and access

- [Tirzepatide Cost Without Insurance](https://glp1tirzepatiderx.com/tirzepatide/cost-without-insurance/): Most people paying for tirzepatide have no coverage at all. Here is the whole cash market, ranked by twelve-month total.
- [Compounded Tirzepatide Cost](https://glp1tirzepatiderx.com/tirzepatide/compounded-tirzepatide-cost/): The cheapest route to the molecule, with a regulatory distinction that deserves to be stated plainly.
- [Cheapest Tirzepatide Online](https://glp1tirzepatiderx.com/tirzepatide/cheapest-online/): The lowest advertised number and the lowest actual number are frequently different programs.
- [Tirzepatide Price Per mg](https://glp1tirzepatiderx.com/tirzepatide/price-per-mg/): Normalize by milligram and the market rearranges itself.
- [Tirzepatide Price by Dose](https://glp1tirzepatiderx.com/tirzepatide/price-by-dose/): The table this whole site exists to publish.
- [Tirzepatide First-Year Cost](https://glp1tirzepatiderx.com/tirzepatide/first-year-cost/): One number, computed the same way for every program on the market.
- [Tirzepatide Maintenance Cost](https://glp1tirzepatiderx.com/tirzepatide/maintenance-cost/): Maintenance is where the money actually goes, because maintenance is most of the treatment.
- [Monthly vs Prepaid Tirzepatide](https://glp1tirzepatiderx.com/tirzepatide/monthly-vs-prepaid/): Prepayment buys a lower rate with money you cannot get back if things change.
- [Tirzepatide Hidden Fees](https://glp1tirzepatiderx.com/tirzepatide/hidden-fees/): The advertised price is a component, not a total. Here is the rest of the invoice.
- [Tirzepatide Membership Fees](https://glp1tirzepatiderx.com/tirzepatide/membership-fees/): A recurring platform charge on top of medication changes the annual total by hundreds.
- [Tirzepatide Shipping Fees](https://glp1tirzepatiderx.com/tirzepatide/shipping-fees/): Shipping a refrigerated biologic is a clinical step, not a logistics footnote.
- [Tirzepatide Lab Fees](https://glp1tirzepatiderx.com/tirzepatide/lab-fees/): A program that asks for bloodwork is doing something a program that asks for nothing is not.
- [Tirzepatide HSA and FSA](https://glp1tirzepatiderx.com/tirzepatide/hsa-fsa/): A prescribed medication is generally eligible. Membership fees are the grey area.
- [Tirzepatide Insurance Coverage](https://glp1tirzepatiderx.com/tirzepatide/insurance-coverage/): Coverage tracks the indication on the prescription more than the molecule in the vial.

## Pharmacy verification

- [How to Verify a Compounding Pharmacy](https://glp1tirzepatiderx.com/pharmacies/how-to-verify/): Five checks, none of which require you to be a pharmacist.
- [503A vs 503B Compounding](https://glp1tirzepatiderx.com/pharmacies/503a-vs-503b/): One dispenses for a named patient. The other manufactures batches under FDA registration.
- [Tirzepatide API Sourcing](https://glp1tirzepatiderx.com/pharmacies/api-sourcing/): The active ingredient has a supply chain, and not all of it is legitimate.
- [Sterility and Potency Testing](https://glp1tirzepatiderx.com/pharmacies/sterility-testing/): An injectable that was never tested for sterility is an injectable you are testing yourself.
- [Tirzepatide Cold Chain](https://glp1tirzepatiderx.com/pharmacies/cold-chain/): The medication is only as good as the coldest and warmest points of its journey.
- [Beyond-Use Dating](https://glp1tirzepatiderx.com/pharmacies/beyond-use-dating/): It is not an expiry date, and it usually arrives before the vial is empty.
- [State Pharmacy Licensing](https://glp1tirzepatiderx.com/pharmacies/state-licensing/): Both the prescriber and the pharmacy need to be licensed where you are.
- [Compounding Pharmacy Red Flags](https://glp1tirzepatiderx.com/pharmacies/red-flags/): Any one of these is enough to walk away from a program.

## Regulatory and market updates

- [FDA and Compounded Tirzepatide](https://glp1tirzepatiderx.com/updates/fda-compounding-tirzepatide/): The rules have moved repeatedly since the shortage. Here is the shape of the current position.
- [Compounded GLP-1 Marketing Enforcement](https://glp1tirzepatiderx.com/updates/compounded-glp1-marketing-enforcement/): The recurring violation is language that makes a compounded preparation sound approved.
- [Tirzepatide Shortage Status](https://glp1tirzepatiderx.com/updates/tirzepatide-shortage-status/): Supply status is the switch that governs how much compounding can lawfully happen.
- [Medicare GLP-1 Coverage](https://glp1tirzepatiderx.com/updates/medicare-glp1-coverage/): Historically excluded, now partially addressed — and the details determine whether you qualify.
- [Brand Self-Pay Pricing](https://glp1tirzepatiderx.com/updates/brand-self-pay-pricing/): A direct-to-patient channel priced well below retail and well above compounded.
- [Oral GLP-1 Pills](https://glp1tirzepatiderx.com/updates/oral-glp1-pills/): A daily tablet changes the competitive floor without matching injectable tirzepatide's effect size.
- [GLP-1 Coverage Withdrawals](https://glp1tirzepatiderx.com/updates/insurance-coverage-withdrawals/): Large employers and plans have repeatedly narrowed weight-management coverage, and patients absorb it mid-treatment.
- [Counterfeit Tirzepatide Alerts](https://glp1tirzepatiderx.com/updates/counterfeit-tirzepatide-alerts/): Falsified product and research-labeled peptide are two different problems with the same outcome.

## Semaglutide comparison cluster

- [Tirzepatide vs Semaglutide](https://glp1tirzepatiderx.com/semaglutide/tirzepatide-vs-semaglutide/): One randomized trial compared them directly. Tirzepatide won on weight; the rest is nuance.
- [Switching to Tirzepatide](https://glp1tirzepatiderx.com/semaglutide/switching-to-tirzepatide/): You restart the ladder. What you do not do is convert your dose across.
- [Compounded Semaglutide Cost](https://glp1tirzepatiderx.com/semaglutide/compounded-semaglutide-cost/): The cheaper molecule, with a smaller effect size in the head-to-head.
- [Semaglutide Dosage](https://glp1tirzepatiderx.com/semaglutide/semaglutide-dosage/): A different ladder, the same four-week logic.
- [Semaglutide Side Effects](https://glp1tirzepatiderx.com/semaglutide/semaglutide-side-effects/): Same family, similar burden, slightly different distribution.
- [Ozempic vs Wegovy](https://glp1tirzepatiderx.com/semaglutide/ozempic-vs-wegovy/): The semaglutide equivalent of the Mounjaro and Zepbound distinction.
- [Wegovy vs Zepbound](https://glp1tirzepatiderx.com/semaglutide/wegovy-vs-zepbound/): Two approved weight-management products, one head-to-head trial between their molecules.
- [Semaglutide vs Tirzepatide Cost](https://glp1tirzepatiderx.com/semaglutide/semaglutide-vs-tirzepatide-cost/): Put the head-to-head result and the annual price difference in the same sentence.
- [Oral Semaglutide](https://glp1tirzepatiderx.com/semaglutide/oral-semaglutide/): A tablet exists for one molecule and not the other, and the fasting requirements matter.
- [Choosing Semaglutide Over Tirzepatide](https://glp1tirzepatiderx.com/semaglutide/who-should-choose-semaglutide/): Three situations where the molecule with the smaller effect size is the better clinical choice.
- [Compounded Semaglutide Safety](https://glp1tirzepatiderx.com/semaglutide/compounded-semaglutide-safety/): The molecule is not the risk. The supply chain is.
- [Semaglutide Results Timeline](https://glp1tirzepatiderx.com/semaglutide/semaglutide-results-timeline/): A 68-week curve, a plateau, and the point where most real-world patients stop.
- [Semaglutide Cost Without Insurance](https://glp1tirzepatiderx.com/semaglutide/semaglutide-cost-without-insurance/): The cheaper molecule, with the same pricing traps.
- [Managing Semaglutide Side Effects](https://glp1tirzepatiderx.com/semaglutide/semaglutide-side-effect-management/): Nausea, constipation, diarrhoea and reflux — and what actually shortens them.
- [Semaglutide and Cardiovascular Outcomes](https://glp1tirzepatiderx.com/semaglutide/semaglutide-and-cardiovascular-outcomes/): The strongest argument for the molecule that loses on weight.
- [Semaglutide Maintenance and Stopping](https://glp1tirzepatiderx.com/semaglutide/semaglutide-maintenance-and-stopping/): Appetite returns first. Then the weight.
- [Semaglutide vs Tirzepatide Side Effects](https://glp1tirzepatiderx.com/semaglutide/semaglutide-vs-tirzepatide-side-effects/): Similar overall burden, one consistent difference, and no reliable way to predict your own experience.
- [Semaglutide Contraindications](https://glp1tirzepatiderx.com/semaglutide/who-should-not-take-semaglutide/): The same two absolutes as tirzepatide, and a similar list of histories that change the conversation.
- [Ozempic Cost](https://glp1tirzepatiderx.com/semaglutide/ozempic-cost/): The diabetes label is the cheapest thing about it.
- [Wegovy Cost](https://glp1tirzepatiderx.com/semaglutide/wegovy-cost/): The weight-management label, and the coverage exclusion that comes with it.
- [Semaglutide Dosage Chart](https://glp1tirzepatiderx.com/semaglutide/semaglutide-dosage-chart/): Five steps to 2.4 mg, four weeks apart, and the same rule about starter doses.
- [Semaglutide Injection and Storage](https://glp1tirzepatiderx.com/semaglutide/semaglutide-injection-and-storage/): Same three sites, same refrigeration rule, different room-temperature windows.
- [Semaglutide Plateau](https://glp1tirzepatiderx.com/semaglutide/semaglutide-plateau/): The STEP curves flatten too. Here is how to tell a plateau from three flat weeks.
- [Oral Semaglutide vs Injection](https://glp1tirzepatiderx.com/semaglutide/oral-semaglutide-vs-injection/): A tablet exists, with conditions attached that decide whether it works for you.

## Journal — data-led analysis

- [Advertised vs Actual Tirzepatide Prices](https://glp1tirzepatiderx.com/journal/advertised-vs-actual-tirzepatide-prices/) (2026-08-05, Investigation): Every published figure we re-checked understated the provider's own price. Four mechanisms explain why the errors never run the other way.
- [The Tirzepatide Dose-Step Tax](https://glp1tirzepatiderx.com/journal/tirzepatide-dose-step-tax/) (2026-08-04, Data): On dose-scaled programs your bill rises exactly as the dose starts working. Here is the increase from 2.5 mg to 15 mg, program by program.
- [Tirzepatide Price Index: Cost Per Milligram, Ranked](https://glp1tirzepatiderx.com/journal/tirzepatide-price-index/) (2026-08-05, Data): Monthly prices are not comparable between doses. Cost per milligram is. Here is the whole tracked market on one honest axis.
- [Zepbound vs Compounded Tirzepatide: What Approval Status Costs](https://glp1tirzepatiderx.com/journal/zepbound-vs-compounded-tirzepatide-cost/) (2026-08-05, Cost): Same molecule, two regulatory statuses, one number that separates them over three years.
- [Tirzepatide Units on an Insulin Syringe](https://glp1tirzepatiderx.com/journal/tirzepatide-units-insulin-syringe/) (2026-08-04, Dosing): The same 10 mg dose is 100 units from one vial and 50 from another. Here is the conversion table, and the error it prevents.
- [What Tirzepatide Weight Loss Looks Like at Your Starting Weight](https://glp1tirzepatiderx.com/journal/tirzepatide-weight-loss-by-starting-weight/) (2026-08-04, Results): Trial percentages converted into pounds, at every starting weight, with what each band buys clinically.
- [Tirzepatide vs Semaglutide: Cost Per Percentage Point of Weight Lost](https://glp1tirzepatiderx.com/journal/tirzepatide-vs-semaglutide-cost-per-point/) (2026-08-03, Analysis): The head-to-head trial result divided by what each molecule costs. The better drug and the better buy are not the same one.
- [How to Switch Tirzepatide Programs Without Losing Your Dose](https://glp1tirzepatiderx.com/journal/switching-tirzepatide-programs/) (2026-08-03, Guide): The six-step sequence that keeps you supplied, at dose, and out of a re-titration you did not need.
- [Tirzepatide Prepaid Plans: What the Discount Actually Costs You](https://glp1tirzepatiderx.com/journal/tirzepatide-prepaid-plans/) (2026-08-02, Cost): Every tracked prepaid discount, beside the sum you cannot get back if anything changes.
- [Tirzepatide Insurance Denial: What Actually Reverses It](https://glp1tirzepatiderx.com/journal/tirzepatide-insurance-appeal-playbook/) (2026-08-02, Insurance): Six denial reasons, what each one really means, and which are documentation failures rather than eligibility failures.
- [Is Tirzepatide Covered by Insurance? The Indication Decides](https://glp1tirzepatiderx.com/journal/tirzepatide-insurance-coverage-by-indication/) (2026-08-01, Insurance): Coverage tracks the diagnosis on the prescription. Here is how each situation is treated, and what it is worth establishing.
- [How to Verify a Compounding Pharmacy in Ten Minutes](https://glp1tirzepatiderx.com/journal/verify-compounding-pharmacy-10-minutes/) (2026-08-01, Safety): Seven free, public checks that need no clinical training, and the disclosure scores of every tracked program.

## News, dated

- 2026-08-05 (Pricing) [We re-checked fifteen compounded prices at source. Fourteen were wrong](https://glp1tirzepatiderx.com/news/compounded-price-corrections-2026/): Every correction moved the price upward, which means published 'cheapest' figures across this category are systematically low.
- 2026-08-05 (Consumer alert) [Embody suspended from our rankings after a documented service-failure pattern](https://glp1tirzepatiderx.com/news/embody-service-failures/): Recent one-star reviews describe payment taken without shipment, unreachable support and unpaid refunds. It held our cheapest tracked price.
- 2026-08-05 (Analysis) [Fewer than a fifth of priced programs will name the pharmacy that makes your medicine](https://glp1tirzepatiderx.com/news/disclosure-gap-quantified/): We scored every tracked programme on what it publishes before you pay. The results are worse than the marketing suggests.
- 2026-08-05 (Consumer alert) [Delivery complaints at Oak Longevity, the cheapest tracked program](https://glp1tirzepatiderx.com/news/oak-longevity-delivery-complaints/): Non-delivery, postal routing and summer heat exposure appear in the negative reviews of a program holding our lowest verified price. It does not meet our suspension threshold.
- 2026-08-04 (Analysis) [Who actually makes your medicine: three ownership structures, three risk profiles](https://glp1tirzepatiderx.com/news/pharmacy-ownership-structures/): Owned pharmacy, single contracted partner, or several named partners. The difference only becomes visible when something goes wrong.
- 2026-07-15 (Consumer alert) [Summer shipping is the season for cold-chain failures](https://glp1tirzepatiderx.com/news/cold-chain-failures-summer/): Warm arrivals cluster in the hottest months, and most programs put the judgement call on the patient.
- 2026-07-01 (Coverage) [Medicare GLP-1 Bridge begins dispensing at $50 a month](https://glp1tirzepatiderx.com/news/medicare-glp1-bridge-launches/): Eligible Part D beneficiaries pay a flat $50 for certain weight-management GLP-1s regardless of dose, under a pilot running to the end of 2027.
- 2026-06-15 (Market) [Compounded GLP-1 access consolidates toward smaller operators](https://glp1tirzepatiderx.com/news/compounded-market-consolidation/): As the large consumer platforms exit, the cheap end of the market is increasingly served by companies most patients have never heard of.
- 2026-06-05 (Market) [Microdose protocols spread, and they are not comparable to standard dosing](https://glp1tirzepatiderx.com/news/microdose-protocols-spread/): Several programs now sell fractional-dose plans at lower prices. They do not map onto the 2.5–15 mg ladder every comparison uses.
- 2026-06-01 (Regulatory) [FDA proposes excluding semaglutide and tirzepatide from the 503B bulks list](https://glp1tirzepatiderx.com/news/503b-bulks-list-proposal/): If finalised, outsourcing facilities would lose a pathway for compounding these molecules at scale.
- 2026-05-20 (Pricing) [Membership stacking spreads: the advertised price is increasingly not the price](https://glp1tirzepatiderx.com/news/membership-stacking-spreads/): Several programs now split the charge into medication plus a mandatory platform fee, which most comparison tables do not add back.
- 2026-05-10 (Coverage) [More employers drop weight-management GLP-1 coverage at plan renewal](https://glp1tirzepatiderx.com/news/employer-coverage-withdrawals-2026/): Withdrawals land mid-treatment, and interruption is the mechanism that undoes results.
- 2026-05-01 (Clinical) [Oral GLP-1 readouts land below injectable tirzepatide on effect size](https://glp1tirzepatiderx.com/news/attain-1-oral-readout/): Convenience and price improve; magnitude does not match the injectable head-to-head.
- 2026-04-20 (Consumer alert) [Alerts continue on counterfeit brand product and research-labelled peptide](https://glp1tirzepatiderx.com/news/counterfeit-and-research-peptide-alerts/): Two different problems, one outcome: an unverified substance in a syringe.
- 2026-04-15 (Regulatory) [Washington State acts against a telehealth company's own compounding pharmacy](https://glp1tirzepatiderx.com/news/washington-state-action-compounding-pharmacy/): When the platform and the pharmacy are the same business, a state action against one is an action against your prescription.
- 2026-04-10 (Pricing) [First-month promotional rates are being published as ongoing prices](https://glp1tirzepatiderx.com/news/promotional-first-month-pricing/): A recurring error across round-ups, and the likely origin of several of the wrong figures we corrected.
- 2026-04-01 (Regulatory) [First oral GLP-1 for weight loss approved, priced from $149](https://glp1tirzepatiderx.com/news/orforglipron-oral-glp1-approved/): An oral small-molecule agent reaches the market at a fraction of injectable brand pricing, with a smaller effect size.
- 2026-04-01 (Coverage) [States gain the option to expand GLP-1 access through Medicaid](https://glp1tirzepatiderx.com/news/state-medicaid-glp1-option/): A route that did not exist for the lowest-income patients — but it is optional, so it will be a patchwork.
- 2026-03-20 (Access) [State exclusion lists keep moving, and programs rarely announce it](https://glp1tirzepatiderx.com/news/state-exclusion-lists-shift/): Availability is set programme by programme and changes without notice — including after you have enrolled.
- 2026-03-15 (Market) [Hims closes its compounded GLP-1 programme to new patients](https://glp1tirzepatiderx.com/news/hims-closes-compounded-programme/): Following a settlement with Novo Nordisk, one of the largest telehealth platforms exits compounded semaglutide, leaving brand-only access.
- 2026-03-10 (Pricing) [Mounjaro joins LillyDirect self-pay at 50–60% below list](https://glp1tirzepatiderx.com/news/mounjaro-joins-lillydirect-self-pay/): The diabetes-labelled tirzepatide gets a cash channel, which changes the calculation for anyone with a type 2 diabetes diagnosis.
- 2026-03-01 (Pricing) [Zepbound KwikPen reaches self-pay pricing and national pharmacy pickup](https://glp1tirzepatiderx.com/news/zepbound-kwikpen-self-pay/): The multi-dose pen joins the vial at $299–$449, and Lilly extends self-pay pickup beyond its own channel.
- 2026-02-23 (Pricing) [Lilly cuts Zepbound self-pay vial pricing to $299–$449](https://glp1tirzepatiderx.com/news/lilly-cuts-zepbound-vial-pricing/): The starter dose drops from $349 to $299 and the 5 mg vial from $499 to $399, with everything above 7.5 mg at $449 on a 45-day refill condition.
- 2026-02-20 (Regulatory) [FDA issues warning letters to compounded GLP-1 telehealth marketers](https://glp1tirzepatiderx.com/news/fda-warning-letters-compounded-glp1/): MEDVi, Ivim Health and the operator of SkinnyRx were among those cited on 20 February 2026 over labelling and marketing claims.
- 2026-02-10 (Consumer alert) [Prepaid plans are where the money gets stuck](https://glp1tirzepatiderx.com/news/prepaid-terms-and-refunds/): Multi-month discounts are real, and so is the fact that compounded medication is generally not refundable once shipped.
- 2026-01-15 (Regulatory) [A year after the shortage was declared over, the compounded market has restructured](https://glp1tirzepatiderx.com/news/tirzepatide-shortage-resolved-effects/): Scope narrowed, large platforms exited, and pricing moved — but patient-specific compounding continues.
- 2025-12-04 (Clinical) [SURMOUNT-5 puts tirzepatide 20.2% against semaglutide 13.7%](https://glp1tirzepatiderx.com/news/surmount-5-head-to-head-readout/): The only randomised head-to-head between the two molecules, and the number every comparison since has leaned on.
- 2025-11-10 (Clinical) [Withdrawal data reframe tirzepatide as maintenance therapy, not a course](https://glp1tirzepatiderx.com/news/surmount-4-withdrawal-evidence/): Participants moved to placebo regained substantially; those who continued held or kept losing.
- 2024-12-20 (Regulatory) [Zepbound approved for obstructive sleep apnoea in adults with obesity](https://glp1tirzepatiderx.com/news/zepbound-osa-indication/): The first drug approved for moderate-to-severe OSA in this population — and a route to coverage that a BMI threshold does not open.

## Interactive tools

- [Twelve-month cost projector](https://glp1tirzepatiderx.com/tools/twelve-month-projector/)
- [Savings calculator](https://glp1tirzepatiderx.com/tools/savings-calculator/)
- [Dose planner](https://glp1tirzepatiderx.com/tools/dose-planner/)
- [Brand vs compounded cost](https://glp1tirzepatiderx.com/tools/brand-vs-compounded/)
- [Legitimacy checker](https://glp1tirzepatiderx.com/tools/legitimacy-checker/)
- [Coverage checker](https://glp1tirzepatiderx.com/tools/coverage-checker/)
- [Titration cost planner](https://glp1tirzepatiderx.com/tools/titration-cost-planner/)
- [Full price calculator](https://glp1tirzepatiderx.com/tirzepatide-price-calculator/)

## Primary sources (every claim on this site traces here)

- [ZEPBOUND (tirzepatide) injection — full prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b) — DailyMed, US National Library of Medicine (Regulatory labeling). Supports: The dose ladder (2.5 mg initiation for four weeks, 2.5 mg increments at intervals of at least four weeks, 15 mg maximum), the statement that 2.5 mg is not approved as a maintenance dosage, injection sites and rotation, storage, contraindications (MTC and MEN 2, serious hypersensitivity), the boxed warning on rodent thyroid C-cell tumours, and the warnings on severe gastrointestinal reactions, acute kidney injury from volume depletion, gallbladder disease and pancreatitis. Accessed 2026-08-05.
- [ZEPBOUND highlights of prescribing information (2026 revision, PDF)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf) — US Food and Drug Administration, Drugs@FDA (Regulatory labeling). Supports: The current approved label including the dosing schedule applying to all approved indications, and the note that routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early MTC detection. Accessed 2026-08-05.
- [FD&C Act provisions that apply to human drug compounding](https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding) — US Food and Drug Administration (Regulatory framework). Supports: The distinction between section 503A compounding by a licensed pharmacist in a state-licensed pharmacy and section 503B compounding within an FDA-registered outsourcing facility, and the different requirements attaching to each. Accessed 2026-08-05.
- [Pharmacy compounding of human drug products under section 503A — final guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacy-compounding-human-drug-products-under-section-503a-federal-food-drug-and-cosmetic-act) — US Food and Drug Administration (Regulatory guidance). Supports: The conditions under which a compounded drug is exempt from new drug approval, current good manufacturing practice and adequate-directions-for-use requirements — that is, why a compounded preparation is lawful without being FDA-approved. Accessed 2026-08-05.
- [Registration for human drug compounding outsourcing facilities under section 503B](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/registration-human-drug-compounding-outsourcing-facilities-under-section-503b-federal-food-drug-and) — US Food and Drug Administration (Regulatory guidance). Supports: What registration as an outsourcing facility involves, used on our 503A versus 503B page. Accessed 2026-08-05.
- [FDA's concerns with unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) — US Food and Drug Administration (Safety communication). Supports: That compounded drugs should only be used where an FDA-approved drug cannot meet the patient's need and should be filled at a state-licensed pharmacy; FDA's import alert on GLP-1 active pharmaceutical ingredient from certain manufacturers; enforcement touching telehealth marketing of retatrutide and API distributors selling it; the existence of fraudulent compounded semaglutide and tirzepatide carrying false product information; and complaints that compounded GLP-1 shipments arrived warm or with inadequate ice packs. Accessed 2026-08-05.
- [FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s](https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s) — US Food and Drug Administration (press announcement) (Enforcement). Supports: That 30 warning letters were issued to telehealth companies for false or misleading claims; that the primary violations were claims implying sameness with FDA-approved products and obscuring product sourcing by branding a compounded product with the telehealth firm's own name; and FDA's statement that compounded drugs are not FDA-approved, are not reviewed for safety, effectiveness or quality before marketing, and are not the same as generic drugs. Accessed 2026-08-05.
- [FDA intends to take action against non-FDA-approved GLP-1 drugs](https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs) — US Food and Drug Administration (commissioner's statement) (Enforcement). Supports: FDA's stated intent to restrict GLP-1 active pharmaceutical ingredients used in non-approved compounded drugs that are mass-marketed as alternatives to approved products, and its position that promotional materials may not claim compounded products are generic versions of, the same as, or clinically proven equivalent to FDA-approved drugs. Accessed 2026-08-05.
- [FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize) — US Food and Drug Administration (Supply status). Supports: That FDA determined the tirzepatide injection shortage resolved on 2 October 2024, and the reminder of legal restrictions on compounding copies of FDA-approved drugs — the regulatory hinge behind the restructuring of the compounded market. Accessed 2026-08-05.
- [Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038) — New England Journal of Medicine 2022;387:205-216 (Randomized controlled trial). Supports: The headline weight-reduction figures at 72 weeks across the 5, 10 and 15 mg arms against placebo, and the adverse-event frequencies quoted throughout the side-effect cluster. Accessed 2026-08-05.
- [SURMOUNT-1 — PubMed record (PMID 35658024)](https://pubmed.ncbi.nlm.nih.gov/35658024/) — PubMed, US National Library of Medicine (Bibliographic record). Supports: Abstract and citation metadata for SURMOUNT-1, for readers without journal access. Accessed 2026-08-05.
- [Tirzepatide after intensive lifestyle intervention (SURMOUNT-3)](https://doi.org/10.1038/s41591-023-02597-w) — Nature Medicine 2023 (Randomized controlled trial). Supports: Weight reduction achieved after a lifestyle-intervention lead-in, used where we distinguish drug effect from lifestyle effect. Accessed 2026-08-05.
- [ClinicalTrials.gov study records](https://clinicaltrials.gov/) — US National Library of Medicine (Trial registry). Supports: Registration, design, population, arms and endpoint for every trial in our library. Each trial page links directly to its own registry record by NCT number. Accessed 2026-08-05.
- [Boards of pharmacy directory](https://nabp.pharmacy/about/boards-of-pharmacy/) — National Association of Boards of Pharmacy (Regulator directory). Supports: How to reach the licensee lookup for each state regulator named on our state pages. Accessed 2026-08-05.
- [BeSafeRx — safely buying prescription medicines online](https://www.fda.gov/drugs/quick-tips-buying-medicines-over-internet/besaferx-your-source-online-pharmacy-information) — US Food and Drug Administration (Consumer guidance). Supports: The consumer-facing checks behind our provider red-flag and verification pages. Accessed 2026-08-05.

Machine-readable: https://glp1tirzepatiderx.com/data/sources.json and https://glp1tirzepatiderx.com/data/sources.csv. Full ledger with deliberately unsourced claims: https://glp1tirzepatiderx.com/sources/


## Trial library

- [SURMOUNT-1](https://glp1tirzepatiderx.com/science/surmount-1/) (2022, tirzepatide): Does tirzepatide cause weight loss in adults with obesity and without diabetes? N Engl J Med 2022;387:205-216. Registry https://clinicaltrials.gov/study/NCT04184622 · DOI https://doi.org/10.1056/NEJMoa2206038
- [SURMOUNT-5](https://glp1tirzepatiderx.com/science/surmount-5/) (2025, tirzepatide): Head-to-head: tirzepatide vs semaglutide for weight loss in adults with obesity and without diabetes. N Engl J Med 2025;392:1929-1942. Registry https://clinicaltrials.gov/study/NCT05822830 · DOI https://doi.org/10.1056/NEJMoa2416394
- [SURMOUNT-4](https://glp1tirzepatiderx.com/science/surmount-4/) (2024, tirzepatide): What happens if you stop tirzepatide after reaching a maintenance dose? JAMA 2024;331:38-48. Registry https://clinicaltrials.gov/study/NCT04660643 · DOI https://doi.org/10.1001/jama.2023.24945
- [SURMOUNT-OSA](https://glp1tirzepatiderx.com/science/surmount-osa/) (2024, tirzepatide): Does tirzepatide treat obstructive sleep apnea in adults with obesity? N Engl J Med 2024;391:1193-1205. Registry https://clinicaltrials.gov/study/NCT05412004 · DOI https://doi.org/10.1056/NEJMoa2404881
- [SURPASS-2](https://glp1tirzepatiderx.com/science/surpass-2/) (2021, tirzepatide): Tirzepatide vs semaglutide 1 mg in type 2 diabetes. N Engl J Med 2021;385:503-515. Registry https://clinicaltrials.gov/study/NCT03987919 · DOI https://doi.org/10.1056/NEJMoa2107519
- [SURPASS-CVOT](https://glp1tirzepatiderx.com/science/surpass-cvot/) (2025, tirzepatide): Cardiovascular outcomes with tirzepatide vs dulaglutide in type 2 diabetes with established ASCVD. N Engl J Med 2025 (presented ADA 2025). Registry https://clinicaltrials.gov/study/NCT04255433 · DOI https://doi.org/10.1056/NEJMoa2500675
- [SUMMIT](https://glp1tirzepatiderx.com/science/summit/) (2025, tirzepatide): Tirzepatide in heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:427-437. Registry https://clinicaltrials.gov/study/NCT04847557 · DOI https://doi.org/10.1056/NEJMoa2410027
- [SURMOUNT-3](https://glp1tirzepatiderx.com/science/surmount-3/) (2023, tirzepatide): Does tirzepatide add further loss after a successful intensive lifestyle program? Nat Med 2023;29:2909-2918. Registry https://clinicaltrials.gov/study/NCT04657016 · DOI https://doi.org/10.1038/s41591-023-02597-w
- [SURMOUNT-2](https://glp1tirzepatiderx.com/science/surmount-2/) (2023, tirzepatide): Tirzepatide for obesity in adults who also have type 2 diabetes. Lancet 2023;402:613-626. Registry https://clinicaltrials.gov/study/NCT04657003 · DOI https://doi.org/10.1016/S0140-6736(23)01200-X
- [ATTAIN-1](https://glp1tirzepatiderx.com/science/attain-1/) (2026, orforglipron): Oral small-molecule GLP-1 (orforglipron) for weight management. N Engl J Med 2025 / FDA approval April 2026. Registry https://clinicaltrials.gov/study/NCT05869903 · DOI https://doi.org/10.1056/NEJMoa2511774
- [STEP-1](https://glp1tirzepatiderx.com/science/step-1/) (2021, semaglutide): Semaglutide 2.4 mg for weight management without diabetes. N Engl J Med 2021;384:989-1002. Registry https://clinicaltrials.gov/study/NCT03548935 · DOI https://doi.org/10.1056/NEJMoa2032183
- [SELECT](https://glp1tirzepatiderx.com/science/select/) (2023, semaglutide): Does semaglutide reduce cardiovascular events in people with obesity but without diabetes? N Engl J Med 2023;389:2221-2232. Registry https://clinicaltrials.gov/study/NCT03574597 · DOI https://doi.org/10.1056/NEJMoa2307563
- [STEP-8](https://glp1tirzepatiderx.com/science/step-8/) (2022, semaglutide): Semaglutide 2.4 mg vs liraglutide 3.0 mg. JAMA 2022;327:138-150. Registry https://clinicaltrials.gov/study/NCT03611582 · DOI https://doi.org/10.1001/jama.2021.23619
- [GIP receptor pharmacology](https://glp1tirzepatiderx.com/science/gip-mechanism/) (2025, tirzepatide): Why does adding GIP agonism to GLP-1 agonism produce more weight loss? Reviews in Cell Metab / Nat Rev Endocrinol 2023–2025. Registry https://clinicaltrials.gov/study/— · DOI https://doi.org/10.1038/s41574-023-00868-7
- [SURPASS-1](https://glp1tirzepatiderx.com/science/surpass-1/) (2021, tirzepatide): Does tirzepatide alone control blood glucose in type 2 diabetes not already on medication? Lancet 2021;398:143-155. Registry https://clinicaltrials.gov/study/NCT03954834 · DOI https://doi.org/10.1016/S0140-6736(21)01324-6
- [SURPASS-3](https://glp1tirzepatiderx.com/science/surpass-3/) (2021, tirzepatide): How does tirzepatide compare with basal insulin added to metformin? Lancet 2021;398:583-598. Registry https://clinicaltrials.gov/study/NCT03882970 · DOI https://doi.org/10.1016/S0140-6736(21)01443-4
- [SURPASS-4](https://glp1tirzepatiderx.com/science/surpass-4/) (2021, tirzepatide): Is tirzepatide safe and effective in people with type 2 diabetes at high cardiovascular risk? Lancet 2021;398:1811-1824. Registry https://clinicaltrials.gov/study/NCT03730662 · DOI https://doi.org/10.1016/S0140-6736(21)02188-7
- [SURPASS J-mono](https://glp1tirzepatiderx.com/science/surpass-j-mono/) (2022, tirzepatide): Does tirzepatide work the same way in a Japanese population? Lancet Diabetes Endocrinol 2022;10:623-633. Registry https://clinicaltrials.gov/study/NCT03861052 · DOI https://doi.org/10.1016/S2213-8587(22)00188-7
- [Tirzepatide cardiovascular meta-analysis](https://glp1tirzepatiderx.com/science/tirzepatide-cv-meta/) (2022, tirzepatide): Does tirzepatide increase cardiovascular risk across the trial programme? Nat Med 2022;28:591-598. Registry https://clinicaltrials.gov/study/Not applicable — pre-specified meta-analysis of registered trials · DOI https://doi.org/10.1038/s41591-022-01707-4
- [Time to weight plateau (SURMOUNT-1 and -4 analysis)](https://glp1tirzepatiderx.com/science/time-to-plateau/) (2025, tirzepatide): When does weight loss on tirzepatide actually stop? Clin Obes 2025. Registry https://clinicaltrials.gov/study/NCT04184622 and NCT04660643 · DOI https://doi.org/10.1111/cob.12734

## Answers to common questions

**How much does tirzepatide cost per month without insurance?**

Compounded tirzepatide from licensed US telehealth programs runs roughly $99 to $299 per month depending on the provider and whether the price is flat or scales with your dose. Brand-name Zepbound through LillyDirect self-pay runs about $299 to $449 per month depending on strength. Retail Zepbound without any program is around $1,089.

**Is compounded tirzepatide the same as Zepbound?**

The active ingredient is the same molecule. Zepbound is FDA-approved, manufactured by Eli Lilly and reviewed by FDA for safety, effectiveness and quality. Compounded tirzepatide is prepared by a state-licensed pharmacy for an individual patient and is not FDA-approved or FDA-reviewed. The pharmacology is identical; the quality assurance structure is not.

**How much weight will I lose on tirzepatide?**

In SURMOUNT-1, mean 72-week weight loss was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, versus 3.1% on placebo. If you have type 2 diabetes, expect roughly two-thirds of those figures based on SURMOUNT-2. Real-world averages run lower than trial averages, mostly because people stop early.

**Is tirzepatide better than semaglutide?**

For weight loss, yes, on the available randomized evidence. SURMOUNT-5 compared them head-to-head over 72 weeks and found 20.2% mean loss on tirzepatide versus 13.7% on semaglutide. Semaglutide retains a stronger cardiovascular outcomes label from the SELECT trial and is cheaper in compounded form.

**What dose of tirzepatide do most people end up on?**

Most people settle between 7.5 mg and 12.5 mg. The efficacy gain from 10 mg to 15 mg was only about 1.4 percentage points in SURMOUNT-1, while side effects and often price continue to rise. Many people never need 15 mg.

**Why do tirzepatide prices go up as my dose increases?**

Because some programs price by dose tier rather than charging one rate. The advertised price usually reflects the 2.5 mg starter dose, which you occupy for about four weeks. Flat-rate programs charge the same amount at every dose. Over twelve months that structural difference typically matters more than any first-month discount.

**What happens if I stop taking tirzepatide?**

Weight regain is expected. In SURMOUNT-4, participants who switched to placebo after 36 weeks regained 14% of body weight over the following year, while those who continued lost a further 5.5%. Obesity behaves as a chronic condition and treatment is generally open-ended.

**Is compounded tirzepatide legal in 2026?**

Yes, when a state-licensed 503A pharmacy prepares it for an identified individual patient with a valid prescription. FDA declared the tirzepatide shortage resolved in December 2024, which ended mass compounding under shortage rules. Patient-specific compounding under section 503A of the Federal Food, Drug, and Cosmetic Act continues.

**Can I use HSA or FSA funds for tirzepatide?**

Generally yes for prescribed weight-management medication, including compounded products, though some plan administrators require a letter of medical necessity. Confirm with your administrator and keep every receipt.

**How long does it take to see results on tirzepatide?**

Appetite change usually arrives within the first one to two weeks, often before the scale moves. Meaningful weight loss typically becomes visible between weeks 4 and 12, with the steepest part of the curve between months 3 and 9. Trial weight loss continued accumulating through week 72.

**Does insurance cover tirzepatide?**

It depends on your plan and your diagnosis. Many commercial plans exclude weight-management drugs entirely. Zepbound carries a specific FDA indication for moderate-to-severe obstructive sleep apnea with obesity, and plans that exclude weight loss often cover a diagnosed sleep disorder. With type 2 diabetes, Mounjaro is on-label.

**What are the most common tirzepatide side effects?**

Nausea (roughly 24–33%), diarrhea (19–23%), constipation (16–17%) and vomiting (8–12%). They cluster in the days after each dose increase and usually settle within one to two weeks at each new dose. Constipation is the one that most often persists.

**Do I need a prescription for tirzepatide?**

Yes, always — for brand and compounded alike. Any seller shipping tirzepatide without a prescription from a licensed prescriber is operating illegally, and the product should not be considered pharmaceutical grade.

**Can I switch from semaglutide to tirzepatide without starting over?**

You restart at 2.5 mg tirzepatide regardless of your semaglutide dose, because there is no equivalence between the molecules. Most switchers find re-titration far easier than a first start — roughly 13% report GI symptoms — because GLP-1 receptor adaptation carries over. Take the first tirzepatide dose about seven days after your last semaglutide injection.

**Why is some tirzepatide advertised under $100 a month?**

Usually one of four reasons: it is the 2.5 mg starter-tier price only, it is an introductory rate that reverts, there is a separate membership fee, or the product is not from a licensed US pharmacy. Ask what you will pay at 10 mg before you enrol.

**What is the difference between a 503A and a 503B pharmacy?**

A 503A pharmacy compounds for an identified individual patient with a prescription and is licensed by a state board of pharmacy. A 503B outsourcing facility registers with FDA, may compound in bulk without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. Most compounded tirzepatide now flows through the 503A pathway.